Photo by impulsq from unsplash
P1.13-18 Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients Y. Shi, P. Xing, X. Han, S. Wang, Y. Liu, P.… Click to show full abstract
P1.13-18 Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients Y. Shi, P. Xing, X. Han, S. Wang, Y. Liu, P. Liu, J. Li, L. Chang, Y. Guan, Z. Zhang, D. Wu, J. Yao, Y. Xin Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing/CN, Department of Clinical Laboratory, National Cancer Center/cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China., Beijing/CN, Geneplus-Beijing Institute, Beijing/CN
Journal Title: Journal of Thoracic Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!